Menopause Associated Vasomotor Symptoms - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: MCC34C0FA9F9EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Menopause Associated Vasomotor Symptoms - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Menopause Associated Vasomotor Symptoms epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Menopause Associated Vasomotor Symptoms Understanding

The DelveInsight Menopause Associated Vasomotor Symptoms epidemiology report gives a thorough understanding of the Menopause Associated Vasomotor Symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Menopause Associated Vasomotor Symptoms in the US, Europe, and Japan. The report covers the detailed information of the Menopause Associated Vasomotor Symptoms epidemiology scenario in seven major countries (US, EU5, and Japan).

Menopause Associated Vasomotor Symptoms Epidemiology Perspective by DelveInsight

The Menopause Associated Vasomotor Symptoms epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Menopause Associated Vasomotor Symptoms epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Menopause Associated Vasomotor Symptoms epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Menopause Associated Vasomotor Symptoms Detailed Epidemiology Segmentation

The Menopause Associated Vasomotor Symptoms epidemiology covered in the report provides historical as well as forecasted Menopause Associated Vasomotor Symptoms epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Menopause Associated Vasomotor Symptoms report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Menopause Associated Vasomotor Symptoms report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Menopause Associated Vasomotor Symptoms Epidemiology Report and Model provide an overview of the global trends of Menopause Associated Vasomotor Symptoms in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Menopause Associated Vasomotor Symptoms in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Menopause Associated Vasomotor Symptoms
• The report provides the segmentation of the Menopause Associated Vasomotor Symptoms epidemiology

Report Highlights

• 11-year Forecast of Menopause Associated Vasomotor Symptoms epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Menopause Associated Vasomotor Symptoms
• Cases of Menopause Associated Vasomotor Symptoms by Mutation Types
• Menopause Associated Vasomotor Symptoms Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Menopause Associated Vasomotor Symptoms?
• What are the key findings pertaining to the Menopause Associated Vasomotor Symptoms epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Menopause Associated Vasomotor Symptoms across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Menopause Associated Vasomotor Symptoms?
• What are the currently available treatments of Menopause Associated Vasomotor Symptoms?

Reasons to buy

The Menopause Associated Vasomotor Symptoms Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Menopause Associated Vasomotor Symptoms market
• Quantify patient populations in the global Menopause Associated Vasomotor Symptoms market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Menopause Associated Vasomotor Symptoms therapeutics in each of the markets covered
• Understand the magnitude of Menopause Associated Vasomotor Symptoms population by its epidemiology
• The Menopause Associated Vasomotor Symptoms Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF MENOPAUSE ASSOCIATED VASOMOTOR SYMPTOMS

3. MENOPAUSE ASSOCIATED VASOMOTOR SYMPTOMS: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Menopause Associated Vasomotor Symptoms Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Menopause Associated Vasomotor Symptoms Treatment and Management
6.2. Menopause Associated Vasomotor Symptoms Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Menopause Associated Vasomotor Symptoms Epidemiology in 7MM (2019-2032)
Table 2: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Menopause Associated Vasomotor Symptoms Epidemiology in the United States (2019-2032)
Table 4: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Menopause Associated Vasomotor Symptoms Epidemiology in Germany (2019-2032)
Table 6: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Menopause Associated Vasomotor Symptoms Epidemiology in France (2019-2032)
Table 8: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Menopause Associated Vasomotor Symptoms Epidemiology in Italy (2019-2032)
Table 10: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Menopause Associated Vasomotor Symptoms Epidemiology in Spain (2019-2032)
Table 12: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Menopause Associated Vasomotor Symptoms Epidemiology in the United Kingdom (2019-2032)
Table 14: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Menopause Associated Vasomotor Symptoms Epidemiology in Japan (2019-2032)
Table 16: Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Menopause Associated Vasomotor Symptoms Epidemiology in 7MM (2019-2032)
Figure 2 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Menopause Associated Vasomotor Symptoms Epidemiology in the United States (2019-2032)
Figure 4 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Menopause Associated Vasomotor Symptoms Epidemiology in Germany (2019-2032)
Figure 6 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Menopause Associated Vasomotor Symptoms Epidemiology in France (2019-2032)
Figure 8 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Menopause Associated Vasomotor Symptoms Epidemiology in Italy (2019-2032)
Figure 10 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Menopause Associated Vasomotor Symptoms Epidemiology in Spain (2019-2032)
Figure 12 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Menopause Associated Vasomotor Symptoms Epidemiology in the United Kingdom (2019-2032)
Figure 14 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Menopause Associated Vasomotor Symptoms Epidemiology in Japan (2019-2032)
Figure 16 Menopause Associated Vasomotor Symptoms Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report